{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.329"},{"groupId":"OG001","value":"0.248"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"230"}],"units":"Participants"}],"description":"Defined as proportion of patients that achieve complete response (CR) or partial response (PR) according to RECIST v1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)","id":"OG000","title":"Arm A"},{"description":"AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)","id":"OG001","title":"Arm B"}],"paramType":"NUMBER","populationDescription":"Patients evaluated for disease","reportingStatus":"POSTED","timeFrame":"24 months","title":"Objective Response Rate (OR: CR or PR)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}